(Q42776121)

7 November 2017

title

Rifaximin for the treatment of hepatic encephalopathy (English)

1 reference

7 November 2017

P S Mantry

1

1 reference

7 November 2017

S Munsaf

series ordinal

2

1 reference

7 November 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

Transplantation Proceedings

7 November 2017

published in

1 reference

7 November 2017

volume

42

1 reference

7 November 2017

issue

10

1 reference

7 November 2017

page(s)

4543-4547

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

7 November 2017

1 reference

Management of cirrhosis and ascites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

7 January 2021

Hepatic Encephalopathy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Management of hepatic encephalopathy: focus on antibiotic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Rifaximin for the treatment of hepatic encephalopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Pathogenetic mechanisms of hepatic encephalopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Current and future developments in travelers' diarrhea therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Rifaximin: in vitro and in vivo antibacterial activity--a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Influence of recent advances in medical management on clinical outcomes of cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Infections in Patients With End-stage Liver Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

The future treatment of portal hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

Rifaximin treatment in hepatic encephalopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.09.173

10.1016/J.TRANSPROCEED.2010.09.173

7 January 2021

Identifiers

DOI

1 reference

7 November 2017

1 reference